Accordingly, MIF blood levels are increased in patients with septic shock, systemic lupus erythematosus, and rheumatoid arthritis (see review by Bilsborrow et al. [90]), a feature for which MIF is regarded as a biomarker and a pharmacological target for different diseases [91,92]. This evidence concerns the gene MIF and systemic lupus erythematosus.